Review



anti gapdh antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Proteintech anti gapdh antibody
    Fstl1 enhances the osteogenic differentiation potential of MC3T3-E1 cells. (A) Representative alkaline-phosphatase (ALP) staining at 7 d. (B) Quantitative ALP activity. (C) Representative Alizarin Red S (ARS) staining at 14 d. (D) Quantification of ARS absorbance (OD 562 ). (E-H) Relative mRNA expression <t>of</t> <t>Runx2,</t> Sp7, Ocn, and Opn at 14 d determined by RT-qPCR. (I) Western-blot bands for RUNX2 and SP7. (J and K) Densitometric ratios of <t>RUNX2/GAPDH</t> and SP7/GAPDH. Sample sizes: con ( n = 3), OE-Fstl1 ( n = 3), and sh-Fstl1 ( n = 3). Data are presented as mean ± SD; inter-group comparisons were performed using 1-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.
    Anti Gapdh Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 27 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fstl1/pmc13050501-80-13-21?v=Proteintech
    Average 93 stars, based on 27 article reviews
    anti gapdh antibody - by Bioz Stars, 2026-07
    93/100 stars

    Images

    1) Product Images from "Follistatin-like protein 1 (FSTL1) modulates bone remodeling and attenuates bone loss in a mouse model of postmenopausal osteoporosis"

    Article Title: Follistatin-like protein 1 (FSTL1) modulates bone remodeling and attenuates bone loss in a mouse model of postmenopausal osteoporosis

    Journal: JBMR Plus

    doi: 10.1093/jbmrpl/ziag037

    Fstl1 enhances the osteogenic differentiation potential of MC3T3-E1 cells. (A) Representative alkaline-phosphatase (ALP) staining at 7 d. (B) Quantitative ALP activity. (C) Representative Alizarin Red S (ARS) staining at 14 d. (D) Quantification of ARS absorbance (OD 562 ). (E-H) Relative mRNA expression of Runx2, Sp7, Ocn, and Opn at 14 d determined by RT-qPCR. (I) Western-blot bands for RUNX2 and SP7. (J and K) Densitometric ratios of RUNX2/GAPDH and SP7/GAPDH. Sample sizes: con ( n = 3), OE-Fstl1 ( n = 3), and sh-Fstl1 ( n = 3). Data are presented as mean ± SD; inter-group comparisons were performed using 1-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.
    Figure Legend Snippet: Fstl1 enhances the osteogenic differentiation potential of MC3T3-E1 cells. (A) Representative alkaline-phosphatase (ALP) staining at 7 d. (B) Quantitative ALP activity. (C) Representative Alizarin Red S (ARS) staining at 14 d. (D) Quantification of ARS absorbance (OD 562 ). (E-H) Relative mRNA expression of Runx2, Sp7, Ocn, and Opn at 14 d determined by RT-qPCR. (I) Western-blot bands for RUNX2 and SP7. (J and K) Densitometric ratios of RUNX2/GAPDH and SP7/GAPDH. Sample sizes: con ( n = 3), OE-Fstl1 ( n = 3), and sh-Fstl1 ( n = 3). Data are presented as mean ± SD; inter-group comparisons were performed using 1-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.

    Techniques Used: Staining, Activity Assay, Expressing, Quantitative RT-PCR, Western Blot

    Fstl1 suppresses the osteoclast-differentiation activity of BMMs. (A) TRAP staining showing TRAP + multinucleated osteoclast morphology in each group. (B) Quantitative analysis of TRAP + osteoclast numbers. (C) Dual staining of F-actin rings (green) and DAPI (blue) illustrating the resorptive synapse structure of mature osteoclasts. (D) Average number of nuclei per TRAP + osteoclast. (E and F) Representative images of resorption pits on an osteoassay surface from each group and quantification of the total resorbed area per well (percentage of surface area). (G-J) Relative mRNA expression of Ctsk, Nfatc1, c-Fos, and Trap determined by RT-qPCR. (K) Western-blot bands for CTSK and NFATc1. (L and M) Densitometric ratios of NFATc1/GAPDH and CTSK/GAPDH. Sample sizes: con ( n = 3), OE-Fstl1 ( n = 3), and sh-Fstl1 ( n = 3). Data are presented as mean ± SD; inter-group comparisons were performed with 1-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.
    Figure Legend Snippet: Fstl1 suppresses the osteoclast-differentiation activity of BMMs. (A) TRAP staining showing TRAP + multinucleated osteoclast morphology in each group. (B) Quantitative analysis of TRAP + osteoclast numbers. (C) Dual staining of F-actin rings (green) and DAPI (blue) illustrating the resorptive synapse structure of mature osteoclasts. (D) Average number of nuclei per TRAP + osteoclast. (E and F) Representative images of resorption pits on an osteoassay surface from each group and quantification of the total resorbed area per well (percentage of surface area). (G-J) Relative mRNA expression of Ctsk, Nfatc1, c-Fos, and Trap determined by RT-qPCR. (K) Western-blot bands for CTSK and NFATc1. (L and M) Densitometric ratios of NFATc1/GAPDH and CTSK/GAPDH. Sample sizes: con ( n = 3), OE-Fstl1 ( n = 3), and sh-Fstl1 ( n = 3). Data are presented as mean ± SD; inter-group comparisons were performed with 1-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.

    Techniques Used: Activity Assay, Staining, Expressing, Quantitative RT-PCR, Western Blot



    Similar Products

    86
    Galectin Therapeutics fstl1
    Fstl1, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fstl1/10__1113_slash_jp291172-7-16-15?v=Galectin+Therapeutics
    Average 86 stars, based on 1 article reviews
    fstl1 - by Bioz Stars, 2026-07
    86/100 stars
      Buy from Supplier

    93
    Proteintech anti gapdh antibody
    Fstl1 enhances the osteogenic differentiation potential of MC3T3-E1 cells. (A) Representative alkaline-phosphatase (ALP) staining at 7 d. (B) Quantitative ALP activity. (C) Representative Alizarin Red S (ARS) staining at 14 d. (D) Quantification of ARS absorbance (OD 562 ). (E-H) Relative mRNA expression <t>of</t> <t>Runx2,</t> Sp7, Ocn, and Opn at 14 d determined by RT-qPCR. (I) Western-blot bands for RUNX2 and SP7. (J and K) Densitometric ratios of <t>RUNX2/GAPDH</t> and SP7/GAPDH. Sample sizes: con ( n = 3), OE-Fstl1 ( n = 3), and sh-Fstl1 ( n = 3). Data are presented as mean ± SD; inter-group comparisons were performed using 1-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.
    Anti Gapdh Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fstl1/pmc13050501-80-13-21?v=Proteintech
    Average 93 stars, based on 1 article reviews
    anti gapdh antibody - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    Proteintech anti fstl1 antibody
    Age-associated down-regulation of <t>FSTL1.</t> (A) Serum FSTL1 concentrations in the normal and osteoporosis groups measured by ELISA. (B) Relative FSTL1 mRNA expression in peripheral blood leukocytes from the 2 groups determined by qPCR. (C) GTEx analysis of sex differences in blood-cell FSTL1 expression. (D) GTEx comparison of FSTL1 expression in individuals aged <50 yr and ≥50 yr. (E) GTEx comparison of FSTL1 expression in individuals aged <70 yr and ≥70 yr. (F) Age-related trend of blood-cell FSTL1 expression in men. (G) Age-related trend of blood-cell FSTL1 expression in women. Data are expressed as mean ± SD; 2-group comparisons were performed with 2-tailed unpaired Student’s t -tests. * p < .05, ** p < .01, ns denotes no significant difference. Transcripts per million (TPM): this is the most used standardized unit in RNA sequencing (RNA-seq) data. It represents the proportion of a certain gene’s transcripts among all transcripts in a specific sample or tissue. After standardization, it enables comparability between different samples and genes.
    Anti Fstl1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fstl1/pmc13050501-80-16-21?v=Proteintech
    Average 93 stars, based on 1 article reviews
    anti fstl1 antibody - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc fstl1 cst wb
    Age-associated down-regulation of <t>FSTL1.</t> (A) Serum FSTL1 concentrations in the normal and osteoporosis groups measured by ELISA. (B) Relative FSTL1 mRNA expression in peripheral blood leukocytes from the 2 groups determined by qPCR. (C) GTEx analysis of sex differences in blood-cell FSTL1 expression. (D) GTEx comparison of FSTL1 expression in individuals aged <50 yr and ≥50 yr. (E) GTEx comparison of FSTL1 expression in individuals aged <70 yr and ≥70 yr. (F) Age-related trend of blood-cell FSTL1 expression in men. (G) Age-related trend of blood-cell FSTL1 expression in women. Data are expressed as mean ± SD; 2-group comparisons were performed with 2-tailed unpaired Student’s t -tests. * p < .05, ** p < .01, ns denotes no significant difference. Transcripts per million (TPM): this is the most used standardized unit in RNA sequencing (RNA-seq) data. It represents the proportion of a certain gene’s transcripts among all transcripts in a specific sample or tissue. After standardization, it enables comparability between different samples and genes.
    Fstl1 Cst Wb, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fstl1/pm41904590-509-20-21?v=Cell+Signaling+Technology+Inc
    Average 86 stars, based on 1 article reviews
    fstl1 cst wb - by Bioz Stars, 2026-07
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc fstl1 antibody
    Age-associated down-regulation of <t>FSTL1.</t> (A) Serum FSTL1 concentrations in the normal and osteoporosis groups measured by ELISA. (B) Relative FSTL1 mRNA expression in peripheral blood leukocytes from the 2 groups determined by qPCR. (C) GTEx analysis of sex differences in blood-cell FSTL1 expression. (D) GTEx comparison of FSTL1 expression in individuals aged <50 yr and ≥50 yr. (E) GTEx comparison of FSTL1 expression in individuals aged <70 yr and ≥70 yr. (F) Age-related trend of blood-cell FSTL1 expression in men. (G) Age-related trend of blood-cell FSTL1 expression in women. Data are expressed as mean ± SD; 2-group comparisons were performed with 2-tailed unpaired Student’s t -tests. * p < .05, ** p < .01, ns denotes no significant difference. Transcripts per million (TPM): this is the most used standardized unit in RNA sequencing (RNA-seq) data. It represents the proportion of a certain gene’s transcripts among all transcripts in a specific sample or tissue. After standardization, it enables comparability between different samples and genes.
    Fstl1 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fstl1/10__1097_slash_mca__0000000000001597-55-0-4?v=Cell+Signaling+Technology+Inc
    Average 86 stars, based on 1 article reviews
    fstl1 antibody - by Bioz Stars, 2026-07
    86/100 stars
      Buy from Supplier

    94
    OriGene human fstl1 protein
    Age-associated down-regulation of <t>FSTL1.</t> (A) Serum FSTL1 concentrations in the normal and osteoporosis groups measured by ELISA. (B) Relative FSTL1 mRNA expression in peripheral blood leukocytes from the 2 groups determined by qPCR. (C) GTEx analysis of sex differences in blood-cell FSTL1 expression. (D) GTEx comparison of FSTL1 expression in individuals aged <50 yr and ≥50 yr. (E) GTEx comparison of FSTL1 expression in individuals aged <70 yr and ≥70 yr. (F) Age-related trend of blood-cell FSTL1 expression in men. (G) Age-related trend of blood-cell FSTL1 expression in women. Data are expressed as mean ± SD; 2-group comparisons were performed with 2-tailed unpaired Student’s t -tests. * p < .05, ** p < .01, ns denotes no significant difference. Transcripts per million (TPM): this is the most used standardized unit in RNA sequencing (RNA-seq) data. It represents the proportion of a certain gene’s transcripts among all transcripts in a specific sample or tissue. After standardization, it enables comparability between different samples and genes.
    Human Fstl1 Protein, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fstl1/pm41616470-60-55-59?v=OriGene
    Average 94 stars, based on 1 article reviews
    human fstl1 protein - by Bioz Stars, 2026-07
    94/100 stars
      Buy from Supplier

    93
    Proteintech tbst anti fstl1
    Age-associated down-regulation of <t>FSTL1.</t> (A) Serum FSTL1 concentrations in the normal and osteoporosis groups measured by ELISA. (B) Relative FSTL1 mRNA expression in peripheral blood leukocytes from the 2 groups determined by qPCR. (C) GTEx analysis of sex differences in blood-cell FSTL1 expression. (D) GTEx comparison of FSTL1 expression in individuals aged <50 yr and ≥50 yr. (E) GTEx comparison of FSTL1 expression in individuals aged <70 yr and ≥70 yr. (F) Age-related trend of blood-cell FSTL1 expression in men. (G) Age-related trend of blood-cell FSTL1 expression in women. Data are expressed as mean ± SD; 2-group comparisons were performed with 2-tailed unpaired Student’s t -tests. * p < .05, ** p < .01, ns denotes no significant difference. Transcripts per million (TPM): this is the most used standardized unit in RNA sequencing (RNA-seq) data. It represents the proportion of a certain gene’s transcripts among all transcripts in a specific sample or tissue. After standardization, it enables comparability between different samples and genes.
    Tbst Anti Fstl1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fstl1/pm41431777-45-8-11?v=Proteintech
    Average 93 stars, based on 1 article reviews
    tbst anti fstl1 - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    Image Search Results


    Fstl1 enhances the osteogenic differentiation potential of MC3T3-E1 cells. (A) Representative alkaline-phosphatase (ALP) staining at 7 d. (B) Quantitative ALP activity. (C) Representative Alizarin Red S (ARS) staining at 14 d. (D) Quantification of ARS absorbance (OD 562 ). (E-H) Relative mRNA expression of Runx2, Sp7, Ocn, and Opn at 14 d determined by RT-qPCR. (I) Western-blot bands for RUNX2 and SP7. (J and K) Densitometric ratios of RUNX2/GAPDH and SP7/GAPDH. Sample sizes: con ( n = 3), OE-Fstl1 ( n = 3), and sh-Fstl1 ( n = 3). Data are presented as mean ± SD; inter-group comparisons were performed using 1-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.

    Journal: JBMR Plus

    Article Title: Follistatin-like protein 1 (FSTL1) modulates bone remodeling and attenuates bone loss in a mouse model of postmenopausal osteoporosis

    doi: 10.1093/jbmrpl/ziag037

    Figure Lengend Snippet: Fstl1 enhances the osteogenic differentiation potential of MC3T3-E1 cells. (A) Representative alkaline-phosphatase (ALP) staining at 7 d. (B) Quantitative ALP activity. (C) Representative Alizarin Red S (ARS) staining at 14 d. (D) Quantification of ARS absorbance (OD 562 ). (E-H) Relative mRNA expression of Runx2, Sp7, Ocn, and Opn at 14 d determined by RT-qPCR. (I) Western-blot bands for RUNX2 and SP7. (J and K) Densitometric ratios of RUNX2/GAPDH and SP7/GAPDH. Sample sizes: con ( n = 3), OE-Fstl1 ( n = 3), and sh-Fstl1 ( n = 3). Data are presented as mean ± SD; inter-group comparisons were performed using 1-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.

    Article Snippet: Antibodies against RUNX2, SP7, NFATC1, and CTSK were purchased from Abcam, while the anti-GAPDH antibody and anti-FSTL1 antibody were obtained from Proteintech.

    Techniques: Staining, Activity Assay, Expressing, Quantitative RT-PCR, Western Blot

    Fstl1 suppresses the osteoclast-differentiation activity of BMMs. (A) TRAP staining showing TRAP + multinucleated osteoclast morphology in each group. (B) Quantitative analysis of TRAP + osteoclast numbers. (C) Dual staining of F-actin rings (green) and DAPI (blue) illustrating the resorptive synapse structure of mature osteoclasts. (D) Average number of nuclei per TRAP + osteoclast. (E and F) Representative images of resorption pits on an osteoassay surface from each group and quantification of the total resorbed area per well (percentage of surface area). (G-J) Relative mRNA expression of Ctsk, Nfatc1, c-Fos, and Trap determined by RT-qPCR. (K) Western-blot bands for CTSK and NFATc1. (L and M) Densitometric ratios of NFATc1/GAPDH and CTSK/GAPDH. Sample sizes: con ( n = 3), OE-Fstl1 ( n = 3), and sh-Fstl1 ( n = 3). Data are presented as mean ± SD; inter-group comparisons were performed with 1-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.

    Journal: JBMR Plus

    Article Title: Follistatin-like protein 1 (FSTL1) modulates bone remodeling and attenuates bone loss in a mouse model of postmenopausal osteoporosis

    doi: 10.1093/jbmrpl/ziag037

    Figure Lengend Snippet: Fstl1 suppresses the osteoclast-differentiation activity of BMMs. (A) TRAP staining showing TRAP + multinucleated osteoclast morphology in each group. (B) Quantitative analysis of TRAP + osteoclast numbers. (C) Dual staining of F-actin rings (green) and DAPI (blue) illustrating the resorptive synapse structure of mature osteoclasts. (D) Average number of nuclei per TRAP + osteoclast. (E and F) Representative images of resorption pits on an osteoassay surface from each group and quantification of the total resorbed area per well (percentage of surface area). (G-J) Relative mRNA expression of Ctsk, Nfatc1, c-Fos, and Trap determined by RT-qPCR. (K) Western-blot bands for CTSK and NFATc1. (L and M) Densitometric ratios of NFATc1/GAPDH and CTSK/GAPDH. Sample sizes: con ( n = 3), OE-Fstl1 ( n = 3), and sh-Fstl1 ( n = 3). Data are presented as mean ± SD; inter-group comparisons were performed with 1-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.

    Article Snippet: Antibodies against RUNX2, SP7, NFATC1, and CTSK were purchased from Abcam, while the anti-GAPDH antibody and anti-FSTL1 antibody were obtained from Proteintech.

    Techniques: Activity Assay, Staining, Expressing, Quantitative RT-PCR, Western Blot

    Age-associated down-regulation of FSTL1. (A) Serum FSTL1 concentrations in the normal and osteoporosis groups measured by ELISA. (B) Relative FSTL1 mRNA expression in peripheral blood leukocytes from the 2 groups determined by qPCR. (C) GTEx analysis of sex differences in blood-cell FSTL1 expression. (D) GTEx comparison of FSTL1 expression in individuals aged <50 yr and ≥50 yr. (E) GTEx comparison of FSTL1 expression in individuals aged <70 yr and ≥70 yr. (F) Age-related trend of blood-cell FSTL1 expression in men. (G) Age-related trend of blood-cell FSTL1 expression in women. Data are expressed as mean ± SD; 2-group comparisons were performed with 2-tailed unpaired Student’s t -tests. * p < .05, ** p < .01, ns denotes no significant difference. Transcripts per million (TPM): this is the most used standardized unit in RNA sequencing (RNA-seq) data. It represents the proportion of a certain gene’s transcripts among all transcripts in a specific sample or tissue. After standardization, it enables comparability between different samples and genes.

    Journal: JBMR Plus

    Article Title: Follistatin-like protein 1 (FSTL1) modulates bone remodeling and attenuates bone loss in a mouse model of postmenopausal osteoporosis

    doi: 10.1093/jbmrpl/ziag037

    Figure Lengend Snippet: Age-associated down-regulation of FSTL1. (A) Serum FSTL1 concentrations in the normal and osteoporosis groups measured by ELISA. (B) Relative FSTL1 mRNA expression in peripheral blood leukocytes from the 2 groups determined by qPCR. (C) GTEx analysis of sex differences in blood-cell FSTL1 expression. (D) GTEx comparison of FSTL1 expression in individuals aged <50 yr and ≥50 yr. (E) GTEx comparison of FSTL1 expression in individuals aged <70 yr and ≥70 yr. (F) Age-related trend of blood-cell FSTL1 expression in men. (G) Age-related trend of blood-cell FSTL1 expression in women. Data are expressed as mean ± SD; 2-group comparisons were performed with 2-tailed unpaired Student’s t -tests. * p < .05, ** p < .01, ns denotes no significant difference. Transcripts per million (TPM): this is the most used standardized unit in RNA sequencing (RNA-seq) data. It represents the proportion of a certain gene’s transcripts among all transcripts in a specific sample or tissue. After standardization, it enables comparability between different samples and genes.

    Article Snippet: Antibodies against RUNX2, SP7, NFATC1, and CTSK were purchased from Abcam, while the anti-GAPDH antibody and anti-FSTL1 antibody were obtained from Proteintech.

    Techniques: Enzyme-linked Immunosorbent Assay, Expressing, Comparison, RNA Sequencing

    Fstl1 haploinsufficiency disrupts bone homeostasis and aggravates OVX-induced bone loss. (A) Three-dimensional micro-CT reconstructions of femora. (B) quantitative micro-CT results. (C) Representative H&E images of distal femoral trabeculae. (D) Quantitative analysis of trabecular area (Tb.Ar) from H&E sections. (E) Osteocalcin (OCN) immunohistochemistry. (F) Quantitative analysis of osteoblast number per bone perimeter (N.Ob/B.Pm, 1/mm) in the indicated experimental groups. (G) TRAP staining depicting osteoclast distribution (red arrows). (H) Quantitative analysis of osteoclast number per bone perimeter (N.Oc/B.Pm, 1/mm) in the indicated experimental groups. Sample sizes: WT-sham ( n = 6), Fstl1 +/− sham ( n = 6), WT-OVX ( n = 6), and Fstl1 +/− OVX ( n = 6). Data are expressed as mean ± SD; group comparisons were conducted with 2-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.

    Journal: JBMR Plus

    Article Title: Follistatin-like protein 1 (FSTL1) modulates bone remodeling and attenuates bone loss in a mouse model of postmenopausal osteoporosis

    doi: 10.1093/jbmrpl/ziag037

    Figure Lengend Snippet: Fstl1 haploinsufficiency disrupts bone homeostasis and aggravates OVX-induced bone loss. (A) Three-dimensional micro-CT reconstructions of femora. (B) quantitative micro-CT results. (C) Representative H&E images of distal femoral trabeculae. (D) Quantitative analysis of trabecular area (Tb.Ar) from H&E sections. (E) Osteocalcin (OCN) immunohistochemistry. (F) Quantitative analysis of osteoblast number per bone perimeter (N.Ob/B.Pm, 1/mm) in the indicated experimental groups. (G) TRAP staining depicting osteoclast distribution (red arrows). (H) Quantitative analysis of osteoclast number per bone perimeter (N.Oc/B.Pm, 1/mm) in the indicated experimental groups. Sample sizes: WT-sham ( n = 6), Fstl1 +/− sham ( n = 6), WT-OVX ( n = 6), and Fstl1 +/− OVX ( n = 6). Data are expressed as mean ± SD; group comparisons were conducted with 2-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.

    Article Snippet: Antibodies against RUNX2, SP7, NFATC1, and CTSK were purchased from Abcam, while the anti-GAPDH antibody and anti-FSTL1 antibody were obtained from Proteintech.

    Techniques: Micro-CT, Immunohistochemistry, Staining

    Fstl1 enhances the osteogenic differentiation potential of MC3T3-E1 cells. (A) Representative alkaline-phosphatase (ALP) staining at 7 d. (B) Quantitative ALP activity. (C) Representative Alizarin Red S (ARS) staining at 14 d. (D) Quantification of ARS absorbance (OD 562 ). (E-H) Relative mRNA expression of Runx2, Sp7, Ocn, and Opn at 14 d determined by RT-qPCR. (I) Western-blot bands for RUNX2 and SP7. (J and K) Densitometric ratios of RUNX2/GAPDH and SP7/GAPDH. Sample sizes: con ( n = 3), OE-Fstl1 ( n = 3), and sh-Fstl1 ( n = 3). Data are presented as mean ± SD; inter-group comparisons were performed using 1-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.

    Journal: JBMR Plus

    Article Title: Follistatin-like protein 1 (FSTL1) modulates bone remodeling and attenuates bone loss in a mouse model of postmenopausal osteoporosis

    doi: 10.1093/jbmrpl/ziag037

    Figure Lengend Snippet: Fstl1 enhances the osteogenic differentiation potential of MC3T3-E1 cells. (A) Representative alkaline-phosphatase (ALP) staining at 7 d. (B) Quantitative ALP activity. (C) Representative Alizarin Red S (ARS) staining at 14 d. (D) Quantification of ARS absorbance (OD 562 ). (E-H) Relative mRNA expression of Runx2, Sp7, Ocn, and Opn at 14 d determined by RT-qPCR. (I) Western-blot bands for RUNX2 and SP7. (J and K) Densitometric ratios of RUNX2/GAPDH and SP7/GAPDH. Sample sizes: con ( n = 3), OE-Fstl1 ( n = 3), and sh-Fstl1 ( n = 3). Data are presented as mean ± SD; inter-group comparisons were performed using 1-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.

    Article Snippet: Antibodies against RUNX2, SP7, NFATC1, and CTSK were purchased from Abcam, while the anti-GAPDH antibody and anti-FSTL1 antibody were obtained from Proteintech.

    Techniques: Staining, Activity Assay, Expressing, Quantitative RT-PCR, Western Blot

    Fstl1 suppresses the osteoclast-differentiation activity of BMMs. (A) TRAP staining showing TRAP + multinucleated osteoclast morphology in each group. (B) Quantitative analysis of TRAP + osteoclast numbers. (C) Dual staining of F-actin rings (green) and DAPI (blue) illustrating the resorptive synapse structure of mature osteoclasts. (D) Average number of nuclei per TRAP + osteoclast. (E and F) Representative images of resorption pits on an osteoassay surface from each group and quantification of the total resorbed area per well (percentage of surface area). (G-J) Relative mRNA expression of Ctsk, Nfatc1, c-Fos, and Trap determined by RT-qPCR. (K) Western-blot bands for CTSK and NFATc1. (L and M) Densitometric ratios of NFATc1/GAPDH and CTSK/GAPDH. Sample sizes: con ( n = 3), OE-Fstl1 ( n = 3), and sh-Fstl1 ( n = 3). Data are presented as mean ± SD; inter-group comparisons were performed with 1-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.

    Journal: JBMR Plus

    Article Title: Follistatin-like protein 1 (FSTL1) modulates bone remodeling and attenuates bone loss in a mouse model of postmenopausal osteoporosis

    doi: 10.1093/jbmrpl/ziag037

    Figure Lengend Snippet: Fstl1 suppresses the osteoclast-differentiation activity of BMMs. (A) TRAP staining showing TRAP + multinucleated osteoclast morphology in each group. (B) Quantitative analysis of TRAP + osteoclast numbers. (C) Dual staining of F-actin rings (green) and DAPI (blue) illustrating the resorptive synapse structure of mature osteoclasts. (D) Average number of nuclei per TRAP + osteoclast. (E and F) Representative images of resorption pits on an osteoassay surface from each group and quantification of the total resorbed area per well (percentage of surface area). (G-J) Relative mRNA expression of Ctsk, Nfatc1, c-Fos, and Trap determined by RT-qPCR. (K) Western-blot bands for CTSK and NFATc1. (L and M) Densitometric ratios of NFATc1/GAPDH and CTSK/GAPDH. Sample sizes: con ( n = 3), OE-Fstl1 ( n = 3), and sh-Fstl1 ( n = 3). Data are presented as mean ± SD; inter-group comparisons were performed with 1-way ANOVA. * p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant.

    Article Snippet: Antibodies against RUNX2, SP7, NFATC1, and CTSK were purchased from Abcam, while the anti-GAPDH antibody and anti-FSTL1 antibody were obtained from Proteintech.

    Techniques: Activity Assay, Staining, Expressing, Quantitative RT-PCR, Western Blot

    Intraperitoneal administration of FSTL1 markedly restores bone mass in OVX mice. (A) Micro-CT three-dimensional reconstructions showing trabecular morphology in femoral cancellous bone. (B) Quantitative micro-CT parameters (BMD, BV/TV, Tb.Th, Tb.N, and Tb.Sp). (C) H&E staining illustrating trabecular architecture. (D) Quantitative analysis of trabecular area fraction (Tb.Ar%). (E) OCN immunohistochemistry depicting osteoblast distribution (red arrows). (F) Quantitative analysis of osteoblast number per bone perimeter (N.Ob/B.Pm, 1/mm) in the indicated experimental groups. (G) TRAP staining depicting osteoclast distribution (red arrows). (H) Quantitative analysis of osteoclast number per bone perimeter (N.Oc/B.Pm, 1/mm) in the indicated experimental groups. Sample sizes: OVX+PBS ( n = 6) and OVX+FSTL1 ( n = 6). Data are expressed as mean ± SD; 2-tailed unpaired Student’s t -tests were used for between-group comparisons. * p < .05, ** p < .01, *** p < .001; ns, not significant.

    Journal: JBMR Plus

    Article Title: Follistatin-like protein 1 (FSTL1) modulates bone remodeling and attenuates bone loss in a mouse model of postmenopausal osteoporosis

    doi: 10.1093/jbmrpl/ziag037

    Figure Lengend Snippet: Intraperitoneal administration of FSTL1 markedly restores bone mass in OVX mice. (A) Micro-CT three-dimensional reconstructions showing trabecular morphology in femoral cancellous bone. (B) Quantitative micro-CT parameters (BMD, BV/TV, Tb.Th, Tb.N, and Tb.Sp). (C) H&E staining illustrating trabecular architecture. (D) Quantitative analysis of trabecular area fraction (Tb.Ar%). (E) OCN immunohistochemistry depicting osteoblast distribution (red arrows). (F) Quantitative analysis of osteoblast number per bone perimeter (N.Ob/B.Pm, 1/mm) in the indicated experimental groups. (G) TRAP staining depicting osteoclast distribution (red arrows). (H) Quantitative analysis of osteoclast number per bone perimeter (N.Oc/B.Pm, 1/mm) in the indicated experimental groups. Sample sizes: OVX+PBS ( n = 6) and OVX+FSTL1 ( n = 6). Data are expressed as mean ± SD; 2-tailed unpaired Student’s t -tests were used for between-group comparisons. * p < .05, ** p < .01, *** p < .001; ns, not significant.

    Article Snippet: Antibodies against RUNX2, SP7, NFATC1, and CTSK were purchased from Abcam, while the anti-GAPDH antibody and anti-FSTL1 antibody were obtained from Proteintech.

    Techniques: Micro-CT, Staining, Immunohistochemistry